Kazia Therapeutics Ltd
KZIA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001075880
No open-market purchases or sales by Kazia Therapeutics Ltd insiders were filed in the last 90 days; 35 institutions reported holding it in 13F filings for Q2 2026, worth $50.7M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Kazia Therapeutics Ltd as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +11 vs. Q3 2025
- Shares held
- 2.48M
- +2.32M (+1,468.5%) vs. Q3 2025
- Total value
- $17.1M
- +$15.9M (+1,397.6%) vs. Q3 2025
- New holders
- 12
- 2 more added
- Sold out
- 1
- 4 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KZIA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 35 | $50.7M |
| Q1 2026 | 23 | $13.0M |
| Q4 2025 | 22 | $17.1M |
| Q3 2025 | 11 | $1.14M |
| Q2 2025 | 10 | $902.9K |
| Q1 2025 | 10 | $120.9K |
| Q4 2024 | 11 | $569.1K |
| Q3 2024 | 18 | $922.0K |
| Q2 2024 | 11 | $89.5K |
| Q1 2024 | 11 | $115.5K |
| Q4 2023 | 18 | $2.15M |
| Q3 2023 | 10 | $235.9K |
| Q2 2023 | 9 | $327.6K |
| Q1 2023 | 8 | $279.4K |
| Q4 2022 | 10 | $262.0K |
| Q3 2022 | 9 | $527.0K |
| Q2 2022 | 12 | $1.24M |
| Q1 2022 | 12 | $2.90M |
| Q4 2021 | 12 | $4.01M |
| Q3 2021 | 18 | $5.03M |
| Q2 2021 | 15 | $4.35M |
| Q1 2021 | 14 | $4.60M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Kazia Therapeutics Ltd; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 738,321 | $5.09M | 0.01% | +738,321 | New |
| Stonepine Capital Management, LLC | 460,359 | $3.17M | 2.51% | +460,359 | New |
| Bleichroeder LP | 400,000 | $2.76M | 0.48% | +400,000 | New |
| Velan Capital Investment Management LP | 300,000 | $2.07M | 1.20% | +300,000 | New |
| Point72 Asset Management, L.P. | 200,000 | $1.38M | 0.00% | +200,000 | New |
| Empery Asset Management, LP | 170,000 | $1.17M | 1.03% | +170,000 | New |
| Corsair Capital Management, L.P. | 70,000 | $470.2K | 0.08% | +70,000 | New |
| Royal Bank of Canada | 54,133 | $373.0K | 0.00% | +54,133 | New |
| Westside Investment Management, Inc. | 30,875 | $212.7K | 0.03% | +30,875 | New |
| Barclays PLC | 23,999 | $165.4K | 0.00% | −10.0% | Reduced |
| Rockefeller Capital Management L.P. | 10,700 | $73.7K | 0.00% | 00.0% | Unchanged |
| Engineers Gate Manager LP | 10,388 | $71.6K | 0.00% | +10,388 | New |
| FNY Investment Advisers, LLC | 7,500 | $51.0K | 0.01% | +7,500 | New |
| Rhumbline Advisers | 1,565 | $10.8K | 0.00% | +974+164.8% | Added |
| Morgan Stanley | 1,000 | $6.89K | 0.00% | +800+400.0% | Added |
| GAMMA Investing LLC | 232 | $1.60K | 0.00% | +232 | New |
| SRS Capital Advisors, Inc. | 200 | $1.38K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 193 | $1.33K | 0.00% | −3,350−94.6% | Reduced |
| Advisor Group Holdings, Inc. | 10 | $68 | 0.00% | 00.0% | Unchanged |
| Dauntless Investment Group, LLC | 1 | $7 | 0.00% | −118,138−100.0% | Reduced |
| Citigroup Inc | 1 | $7 | 0.00% | −638−99.8% | Reduced |
| Allworth Financial LP | 1 | $7 | 0.00% | 00.0% | Unchanged |
| MAI Capital Management | 0 | $0 | 0.00% | −52−100.0% | Sold out |